Throughout the last three months, 14 analysts have evaluated Regeneron Pharmaceuticals REGN, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 6 | 3 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 3 | 1 | 0 |
| 3M Ago | 2 | 3 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1057.0, a high estimate of $1200.00, and a low estimate of $720.00. Marking an increase of 0.27%, the current average surpasses the previous average price target of $1054.14.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Raises | Outperform | $1200.00 | $1185.00 |
| Cory Kasimov | Evercore ISI Group | Announces | Outperform | $1150.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Tyler Van Buren | TD Cowen | Raises | Buy | $1030.00 | $1020.00 |
| Colin Bristow | UBS | Raises | Buy | $1099.00 | $1090.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Geoff Meacham | B of A Securities | Raises | Underperform | $720.00 | $710.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1189.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1135.00 | $1135.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1135.00 | $1135.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $1115.00 | $1104.00 |
| William Pickering | Bernstein | Announces | Outperform | $1125.00 | - |
| Aaron Gal | Bernstein | Announces | Outperform | $1125.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Regeneron Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Regeneron Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regeneron Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Key Indicators: Regeneron Pharmaceuticals's Financial Health
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Regeneron Pharmaceuticals's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -0.54%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 22.96%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 2.73%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
